## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: DELANY et al.
Serial No.: To be assigned
Filed: Concurrently herewith
For: HUMAN VANILLOID RECEPTORS AND THEIR USES
Assistant Commissioner for Patents Washington, D.C. 20231
INFORMATION DISCLOSURE STATEMENT
Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97
[ ] Copies of the references are enclosed
[ ] Copies of the references were submitted in parent application Serial No (37 CFR 1.98(d))
[X] A copy of the International Search Report which issued on International Application No.  PCT/EP99/09284 is submitted herewith. All of the publications cited in the International Search Report or International Preliminary Examination Report are listed on the attached form PTO-1449. (37 CFR 1.98(d)), and applicants understand that copies have been supplied to the USPTO by the International Bureau.
A. [X] The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b)
B. [] The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:
<ul><li>(1) a final action under § 1.113 or</li><li>(2) a notice of allowance under § 1.311,</li></ul>
whichever occurs first.
[ ] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
[ ] Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$200.00).
C. [ ] The Information Disclosure Statement transmitted herewith is being filed after a final action under

issue fee.

[ ] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

[ ] Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).

[ ] The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

[X] Please charge required fees to Deposit Account No. 07-1392.

[ ] A duplicate copy of this paper is attached.

Date: Jane / , 2001

Respectfully Submitted,

Frank P. Grassler

Attorney of Record, Reg. No. 31,164

GlaxoSmithKline Five Moore Drive, P.O. Box 13398 Research Triangle Park, NC 27709 (919) 483-1007

CERTIFICATE OF EXPRESS MAILING (37 CFR 1.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Assistant Commissioner of Patents and Trademarks, Washington, D.C. 20231 on

Date: 4/01/61

Marilyn Eldridge

JC: C'd PCT/PTO 0 1 JON 2001

FORM PTO-1449					ATTORNEY DOCKET		SERIAL NO.		
INFORMATION DISCLOSURE STATEMENT					NO. PG3606USW		To be assigned		
					APPLICANT DELANY et al.				
					FILING DATE		GROUP		
					Concurrently herewith				
			U.S. P	ATENT D	OCUMENTS				
						<u> </u>		Filing Date	
Examiner Initials		Patent Number	Issue Date	1	Name	Class	Subclass	If Appropriate	
							<del></del>	<del>                                     </del>	
	<del> </del> -						<u> </u>		
	l		Co	ntinue on	page		<u> </u>		
					T DOCUMENT	rs			
		Document	Publication					Translation Yes   No	
		Number	Date		Country	Class	Subclass	165   140	
	BA	WO9937675A	29 July 1999	PCT					
	BB	EP 0943 683A	22 Sept	EP					
	<u> </u>		1999						
	-		· · · · · ·				-	<u> </u>	
	+	<del>                                     </del>			<del> </del>	-			
	1	<u> </u>	Co	ontinue on	page	•			
	Oï	THER DOCUME	NTS (Includi	ng Author	, Title, Journal	-Date, Page N	umber, Etc.)		
	CA	Caterina, M.J. et al., The capsaicin receptor: a heat-activated ion channel in the pain pathway, Nature 389(6653):816-824 (1997)							
	CB	EMBL Database, Heidelberg, FRG Emest2 accession number AA700891 22 December 1997,							
		Hillier, L. et al.:zj40d01.s1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNA clone 452737 3', XP002135285,							
	.CC	EMBL Database, Heidelberg, FRG Emest6 accession number AI089668, 19 August 1998,							
		NCI/NINDS-CGAP: "qa10f06.x1 NCI_CGAP_Brn23 Homo sapiens cDNA clone IMAGE:1686371 3'", XP002135285,							
	CD	Biro, T.et al., Recent Advances in Understanding of Vanilloid Receptors: A Therapeutic Target for							
		Treatment of Pain and Inflammation in Skin, Journal of Investigative Dermatology Symposium Proceedings, 2(1):56-60 (1997)							
			<u> </u>						
			-		:				
	1					-			
				. ==					
						- All de			
						··-			
	<u> </u>								
				<del></del>	<del> </del>				
	770		C	ontinue or	page	I DAGE	CONGIDENT		
EXAMINER						DATE	CONSIDEREI	,	
EXAMINE through cit	ER: In	itial if citation cor f not in conforma	nsidered, wheth	ner or not on a sidered. I	itation is in connected	formance with this form with	MPEP § 609; I	Oraw line ation to the	

applicant.